Elicera has entered into agreements with Mangold regarding the position as Certified Adviser and Liquidity provider. Mangold will take over as Certified Adviser and Liquidity provider on
Elicera is consequently increasing the cooperation with Mangold , that recently has acted as financial advisor for the recently completed new issue.
For further information please contact:
Phone: +46 (0) 703 31 90 51
jamal.elmosleh@elicera.com
Certified Adviser
The Company's Certified Adviser is
The information was submitted for publication distributed through the contact person below at 08;13 CET on
About the iTANK platform
The iTANK technology platform has been developed for arming and enhancing CAR T-cells to meet two of the major challenges CAR T-cell therapies face in the treatment of solid tumors: a very diverse set of tumor antigen targets and a very hostile tumor microenvironment. The technology is used to incorporate a transgene into CAR T-cells encoding a neutrophil activating bacterial protein (NAP). NAP secreted from the CAR(NAP) T-cells has been shown to be able to enhance the function of CAR T-cells and importantly activating a parallel bystander immune response against the cancer via CD8+ killer T-cells. This is expected to lead to a broad attack against most antigen targets on cancer cells. The iTANK platform is used to enhance the company's own CAR T-cells but can also be universally applied to other CAR T-cell therapies under development. Proof-of-concept data was published in Nature Biomedical Engineering in
About
https://news.cision.com/elicera-therapeutics/r/elicera-therapeutics-changes-certified-adviser-and-liquidity-provider-to-mangold-fondkommission-ab,c3946904
https://mb.cision.com/Main/20218/3946904/2673627.pdf
(c) 2024 Cision. All rights reserved., source